Phase I Study of Anti-GARP CAR T Cell Therapy Delivered into the Brain Cavity for Recurrent Grade III or IV Gliomas
Led by Ohio State University Comprehensive Cancer Center · Updated on 2026-05-08
30
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new treatment called anti-GARP chimeric antigen receptor CAR T cell therapy for patients with recurrent grade III or IV gliomas, which are high-grade brain tumors that have returned after initial improvement. This phase I trial aims to assess the safety, side effects, and best dose of this therapy. CAR T-cell therapy involves modifying a patients immune cells to better attack tumor cells. The study also plans to explore how the therapy affects the immune response and tumor activity over time, including survival outcomes and tumor marker expression.
Participants undergo a series of procedures starting with apheresis to collect their T cells, followed by surgery to place a cerebrospinal fluid CSF reservoir. The modified anti-GARP CAR T cells are then infused directly into the brain cavity on days 14, 21, 28, 35, and 42 if the disease does not progress or unacceptable side effects occur. Throughout the study, patients receive various scans and tests such as echocardiography or MUGA, chest x-rays, MRI scans, lumbar punctures, and blood and CSF sample collections to monitor safety and treatment effects.
During the trial, participants will be closely monitored for dose-limiting toxicities up to 30 days after the first dose. Adverse events, immune cell characteristics, cytokine levels, tumor responses by imaging, progression-free and overall survival will be tracked for up to 15 years. Follow-up visits occur frequently in the first months and then annually for at least 15 years. This long-term monitoring helps researchers understand the therapys lasting effects and safety.
CONDITIONS
Brief Title
Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
Research Team
O
Ohio State University Comprehensive Cancer Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Intracavitary anti-GARP chimeric antigen receptor T cell therapy
Current best established treatment for recurrent high-grade glioma
What it is
A laboratory-manufactured immunotherapy in which autologous T cells are engineered with a chimeric antigen receptor targeting GARP, administered directly into the brain cavity after tumor resection.
Maximal safe surgical resection of the tumor, followed by best available post-operative therapy such as radiotherapy (if not previously exhausted) or chemotherapy, tailored according to performance status and prior treatment exposures per contemporary guidelines.
Role in the trial
Investigational therapy directly tested in eligible trial participants after surgical resection.
Not included as a control comparator within the trial; presented here for interpretive context only.
Primary use
Researching the safety, persistence, and anti-tumor effect of anti-GARP CAR-T cell therapy in the post-surgical cavity of recurrent high-grade glioma.
Reducing tumor volume, prolonging survival, and achieving disease control through established surgical and adjuvant approaches.
How it is given or performed
Autologous T cells are harvested, genetically modified in the laboratory, and infused directly into the cavity left by surgical tumor resection.
Surgical removal of the tumor is performed when feasible, followed by radiotherapy or chemotherapy via oral or intravenous routine clinical practice.
Evidence status
Early-phase study in highly selected, recurrent glioma patients. No published efficacy results yet. Laboratory studies suggest tumor-specific targeting but clinical benefit must be established.
Established treatment approaches deliver modest disease control with limited survival benefit. Most patients with recurrent high-grade glioma experience disease progression despite surgery and available adjuvant therapies.
Important limitations
The therapy is experimental, with unknown risks and benefits. Enrollment criteria are strict. Manufacturing complexity and invasive delivery limit generalizability. Long-term outcomes are unproven.
Standard therapies for recurrent glioma remain palliative with limited impact on survival. Tumor progression is common, and eligibility for surgery varies. Systemic therapies often provide only brief disease control.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Patients are 18 years old or older
Capacity to understand and provide written informed consent
Diagnosis or clinical suspicion of recurrent malignant glioma (WHO grade III or IV) or prior grade II glioma with new findings
Imaging or biopsy confirmation of recurrent disease with measurable tumor by RANO criteria
Unifocal disease in one brain hemisphere, not in critical brain areas
If on steroids, must be low dose (4 mg/day or less) and stable before treatment
No prior or planned bevacizumab therapy
Karnofsky performance score 60 or higher
Candidate for surgery with intent to resect over 80-90% of tumor
White blood cells above 4,000 cells/uL
Hemoglobin above 7 gm/dL
Platelets above 100/dL
Kidney and liver function within 1.5 times normal limits
Negative pregnancy test for women of reproductive potential
Use of approved contraceptives and refraining from sperm donation during and after treatment
Sufficient venous access for apheresis
Life expectancy greater than 12 weeks
Clinical judgement of ability to complete trial and maintain stable neurological symptoms
You will not qualify if you...
History of other malignancies except certain treated cancers without relapse
History of autoimmune disease or need for high-dose steroids or immunosuppressives
Concurrent treatment with other investigational agents
Recent chemotherapy or other anti-cancer treatments within 14 days before apheresis
Active infections requiring IV antimicrobials or invasive fungal infections
Allergy to study products or components
Uncontrolled seizures within the last 3 months
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
. Participants undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) and other assessments during screening.
Run-in Period
Duration - Approximately 2 weeks before surgery
Participants undergo apheresis to collect cells before surgery.
1 visit for apheresis
Surgery
Duration - 1 day
Participants undergo surgery for tumor resection and placement of a cerebrospinal fluid (CSF) reservoir.
1 surgical procedure visit (in-person)
Treatment
Duration - From Day 14 to Day 42
Participants receive anti-GARP CAR T cell therapy via intracavitary infusions on multiple days if there is no disease progression or unacceptable toxicity.
5 intracavitary infusion visits on Days 14, 21, 28, 35, and 42
Post-operative Follow-up
Duration - Up to 15 years
Participants have regular assessments including collection of cerebrospinal fluid (CSF) and blood samples, lumbar punctures, chest x-rays, and magnetic resonance imaging (MRI) to monitor safety and response.
Follow-up visits at 2 weeks, then at 3, 4, 6, 8, 12, and 24 months, then annually for at least 15 years
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Comparison of Selumetinib Versus Carboplatin and Vincristine for Newly Diagnosed or Untreated Low-Grade Glioma Without BRAFV600E Mutation or Neurofibromatosis Type 1
Evaluation of Ga-68 PSMA-11 PETCT Imaging to Detect Recurrence or Progression in Adults With High-Grade Glioma
Phase I Study of Anti-GARP CAR T Cell Therapy Delivered into the Brain Cavity for Recurrent Grade III or IV Gliomas
Randomized Trial of Continuous Glucose Monitoring Versus Standard Monitoring for Blood Sugar Control in Adults with Glioblastoma
Phase III Study of Lutathera for Recurrent or Progressive High-Grade CNS Tumors and Meningiomas Showing Uptake on DOTATATE PET
Evaluating Stem Cell-Delivered Oncolytic Adenovirus DNX-2401 via Intra-Arterial Injection for Recurrent High-Grade Glioma Treatment
Phase II Study of Retifanlimab Combined with Bevacizumab and Hypofractionated Radiotherapy for Adults with Recurrent Glioblastoma
Study of Triapine and Temozolomide Combination Therapy for Recurrent Glioblastoma Evaluating Safety, Dosage, and Treatment Effects